CTRI/2020/10/028627尚未招募1 期
An Assessor-Blind, Randomized, Three-Treatment, Three-Period, Single-Dose, Crossover, Bioequivalence Study of INTG8of Intas Pharmaceuticals Limited, India to Forteo® (Lilly USA,LLC) and Forsteo® (Eli Lilly Nederland B.V., The Netherlands)in Healthy Men and Postmenopausal Women after SubcutaneousAdministration
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Non-smokers, Non-tobacco users, normal, healthy, adult, human male subjects between 18 and 45 years of age (both inclusive) and postmenopausal women subjects between 45 and 65 years of age (both inclusive).
- •2.Having a Body Mass Index (BMI) between 18.5 to 30 (both inclusive), calculated as weight in kg per height in m2.
- •3.Postmenopausal women with serum FSH levels greater than 40 mIU per mL:
- •Postmenopausal women include women with 6 months of spontaneous amenorrhea
- •6-week post-surgical bilateral oophorectomy with or without hysterectomy prior to the start of the study (Investigator may request the official report to confirm the surgery date and exclude cancer as the cause needing surgery).
- •4.Able to comply with the study procedures, in the opinion of the Principal Investigator.
- •5.Able to give voluntary written informed consent for participation in the trial.
- •6.Serum pregnancy test at the time of screening must be negative (for females).
排除标准
- •1.Known hypersensitivity or idiosyncratic reaction to Teriparatide its ingredients (glacial acetic acid, sodium acetate, mannitol, metacresol, hydrochloric acid, sodium hydroxide solution) or any related drug.
- •2.Subjects with known latex allergies.
- •3.Subjects assessed for orthostatic hypotension (Defined as decrease in systolic blood pressure of 20 mm Hg or a decrease in diastolic blood pressure of 10 mm Hg within 3 minutes in standing position when compared with blood pressure from sitting or supine position with clinical symptoms) and confirmed unsafe for study inclusion by the investigator.
- •4.Subjects with systemic hypotension (Below 90 mm Hg systolic blood pressure in sitting position) and considered unfit for trial by the investigator.
- •5.History or presence of any disease or disorder known to influence bone metabolism, compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •6.History or presence of metabolic bone disease, active or recent urolithiasis, hypercalcemia and hypercalcaemic disorders, osteosarcoma or Pagetâ??s disease of bone, prior external beam or implant radiation therapy involving the skeleton.
- •7.Subjects with history of ingestion of medicine (including herbal remedies) at any time within 14 days prior to dosing in period-I. In any such case, subject selection will be at the discretion of the Principal Investigator.
- •8.Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or NSAID induced urticaria.
- •9.A recent history of harmful use of alcohol (less than 2 years), i.e., alcohol consumption of more than 14 standard drinks for men and 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40 percentage distilled spirits, such as rum, whisky, brandy, etc.) or Consumption of alcohol or alcoholic products within 48 hours prior to receiving the study drug in period-I.
- •10.Smokers or tobacco users, who consumed tobacco or tobacco-containing products (gutkha, pan/pan masala, beedi, cigarettes, others) within 6 months prior to start of the study or has inability to abstain from smoking during the study period.
- •11.Having any significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12-lead ECG, Abdominal-pelvis ultrasonography (for females) and X-ray chest (postero-anterior view) recordings.
- •12.Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
- •13.History or presence of psychiatric disorders.
- •14.A history of difficulty with donating blood.
- •15.Donation of blood (1 unit or 350 mL) or receipt of an investigational drug or product or participation in a drug research study within 6 months prior to receiving the first dose of the study medicine (or longer as per local regulatory requirement).
- •16.A positive hepatitis screen including hepatitis B surface antigen and or or HCV antibodies.
- •17.A positive test result for HIV (1 and/ or 2) antibody.
- •18.Consumption of grapefruit or grapefruit products within 72 hours prior to dosing in period-I.
- •19.Male subject with hemoglobin level less than 11.1 gm per dL and female subjects with hemoglobin level less than
研究者
相似试验
尚未招募
1 期
A Study of INTG8 in Healthy Men and Postmenopausal WomeCTRI/2018/09/015697INTAS PHARMACEUTICALS LIMITED
尚未招募
1 期
A bioequivalence study of a bevacizumab biosimilar in healthy male subjectsCTRI/2019/02/017428Intas Pharmaceuticals Limited
进行中（未招募）
1 期
A trial to investigate the efffect of a SGLT-2 inhibitor a DPP-4 inhibitor and a SGLT-2 inhibitor + DPP-4 inhibitor on glucagon levels, endogenous glucose production and lipolysis.Diabetes mellitus type 2MedDRA version: 19.0Level: LLTClassification code 10012594Term: DiabetesSystem Organ Class: 100000004861EUCTR2015-004637-27-ATMedizinische Universität Graz18
尚未招募
4 期
A study toassess the effect of probiotic on the risk of recurrenceand severity of symptoms in females with recurrent vulvovaginal candidiasisCTRI/2024/07/071175Dr Malwina Naghibi
进行中（未招募）
Unknown
A single dose three-way crossover oral bioavailability study of ß-alanine capsules in comparison with conventional ß-alanine in healthy human volunteers in fasting conditionsCTRI/2024/03/063457atural Alternatives International